ArticleNeurosciences (Riyadh, Saudi Arabia)2025
Impact of Qihuang needle therapy combined with flunarizine hydrochloride for vertigo in vestibular migraine.
Article in Neurosciences (Riyadh, Saudi Arabia), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the impact of QHN combined with FH versus FH monotherapy on vestibular migraine (VM)
methodsThe study included patients treated for VM with either QHN+FH or FH alone between September 2022 and September 2023 at The First Affiliated Hospital of Guangdong Pharmaceutical University in Guangzhou, Guangdong Province, China. The primary outcome was the change of Dizziness Handicap Inventory (DHI) before and after 8 weeks of treatment. Secondary outcomes included changes in the Video Head Impulse Test (v-HIT) results before and after 8 weeks of treatment, and the recurrence of vertigo attacks at 4 and 8 weeks post-treatment.
resultsThis study included 59 patients, with 29 receiving QHN+FH treatment and 30 receiving FH monotherapy. Both the QHN+FH and FH groups showed significant reductions in DHI scores before and after treatment. After treatment, the QHN+FH group demonstrated an improvement in v-HIT (0.74±0.14 vs. 0.64±0.14,
conclusionThis study suggested that QHN combined with FH might had a potential advantage in improving treatment outcomes and reducing short-term recurrence of vertigo in VM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.